The Medical Letter on Drugs and Therapeutics
Clarithromycin in Patients with Coronary Artery Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has warned that use of the macrolide antibiotic clarithromycin (Biaxin, and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.1

Clarithromycin is often used as part of a four-drug regimen to treat Helicobacter pylori infection. It is also indicated for treatment of various respiratory tract infections, but is generally not a drug of choice because of increasing resistance of respiratory pathogens to macrolides. Alternatives to clarithromycin for these indications are listed in Table 1.

THE CLINICAL STUDY — The FDA warning was based on the results of a double-blind trial (CLARICOR) evaluating whether the anti-infective and anti-inflammatory properties of clarithromycin would reduce mortality in patients with stable coronary artery disease. In the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clarithromycin in Patients with Coronary Artery Disease
Article code: 1547d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian